The forced overexpression of c-Myc in mouse prostate and in normal human prostate epithelial cells results in tumor transformation with an invasive phenotype. How c-Myc regulates cell invasion is poorly understood. In this study, we have investigated the interplay of c-Myc and androgens in the regulation of prostate cancer cell invasion. We found that c-Myc induces cell invasion and anchorageindependent growth by regulating ezrin protein expression in the presence of androgens. The activity of the ezrin promoter is controlled by androgens through c-Myc, which binds to a phylogenetically conserved E-Box located in the proximal promoter region. Besides, we also show that ezrin is an important regulator of c-Myc protein levels. These effects are achieved through androgeninduced changes in ezrin phosphorylation, which results in the regulation of downstream signals. These downstream signals involve the modulation of Akt and GSK-3b activity resulting in increased c-Myc protein synthesis and inhibition of its degradation. In summary, we have shown a key role for ezrin as a mediator of c-Myc-induced tumorigenesis in prostate cancer cells.
Introduction
In 2007, approximately 10% of the 220 000 men who were diagnosed with prostate cancer (PCa) in the USA will eventually die secondary to metastasis (Taichman et al., 2007) . The mechanisms underlying PCa metastatic progression are still poorly understood. The clinical evidence indicates that androgen-regulated pathways have a role in metastasis, because androgen ablation therapy is a very effective treatment for metastatic PCa and results in clinical remission in 80-90% of patients (Hellerstedt and Pienta, 2003) .
Metastatic progression of PCa is characterized by a set of preferred genetic lesions (Lapointe et al., 2007; Sun et al., 2007) . Amplification of 8q24, the region containing the c-Myc gene, is the most commonly observed genetic alteration associated with PCa metastasis, being observed in approximately 50% of clinically presented metastatic tumors. The key roles of c-Myc in PCa metastatic progression have been shown in mouse models, where cMyc overexpression in the prostate results in adenocarcinomas that progress into an invasive stage and form metastatic lesions (Wang et al., 2003) . Retroviral expression of c-Myc can immortalize normal human prostatic epithelium, transforming it into a metastatic tumor and conferring androgen-independent growth (Gil et al., 2005; Williams et al., 2005) .
In a previous study, we demonstrated that androgens, in addition to their effects on proliferation, also promote PCa cell invasion. These findings provide a possible mechanistic explanation for the clinical effects of androgen ablation therapy on metastatic, treatment naive tumors. The androgens effect on PCa cell invasion requires the activation of ezrin. This is achieved by a dual mechanism where androgens induces ezrin gene expression and the posttranslational activation of ezrin through PKCa and Src kinases (Chuan et al., 2006) . Studies have shown a positive correlation of ezrin expression levels with Gleason score and seminal vesicle invasion (Pang et al., 2004a) . The induction of ezrin gene expression by androgens is exerted indirectly and requires a de novo synthesis of an effector molecule that is yet unknown (Chuan et al., 2006) . Because of the importance of the c-Myc protein in PCa progression, we hypothesized that c-Myc could have a role in ezrin regulation. Here, we investigate the function of c-Myc in the regulation of PCa cell invasion and the contribution of ezrin to this process.
Results

c-Myc regulates PCa cells invasion in vitro
Numerous studies have shown that both c-Myc and androgens (through the androgen receptor, AR) are involved in PCa progression (Sadi and Barrack, 1991; Bouchard et al., 1998; Sawyer, 2004) . To clarify how c-Myc and androgens interact to control the metastatic properties of PCa cells, we studied how changes in c-Myc expression affect PCa cell invasion on androgens stimulation. As shown in Figures 1a and b , treatment of LNCaP-FGC PCa cells with synthetic androgen R1881 increased c-Myc mRNA and protein levels within 2 h of treatment and this effect was sustained for at least 8 h. The effect of R1881 was blocked by the AR antagonist bicalutamide, indicating the involvement of the AR. Because ezrin is required for androgen-induced invasion (Chuan et al., 2006) , we measured ezrin levels in c-Myc expressing cells. As we have previously demonstrated, androgens treatment increases ezrin levels (Chuan et al., 2006) . This effect could be mimicked by c-Myc overexpression alone, in the absence of hormone, and was enhanced on androgen treatment ( Figure 1c ). We also analyzed a set of PCa (n ¼ 10) and benign prostatic hyperplasia (n ¼ 4) samples for co-expression of c-Myc and ezrin by immunofluorescence and confirmed that in all samples analyzed there is a significant overlap between c-Myc and ezrin expression levels in epithelial cells (Supplementary Figure 1) . Although c-Myc overexpression stimulated cell proliferation in an androgenindependent manner (Supplementary Figure 2A ; Bernard et al., 2003) , little cell invasion is observed in the absence of androgen stimulation in cells overexpressing c-Myc (Figure 1c) . Conversely, cells overexpressing c-Myc protein show a significantly increased invasive capacity on androgen treatment.
Our findings suggest that c-Myc exert its effect upstream of ezrin to regulate androgens-induced invasion. To test this hypothesis, we used Short-interfering (siRNA) to knock down c-Myc expression in LNCaP-FGC cells. Two siRNAs targeting c-Myc, but not a control siRNA, decreased expression of c-Myc (Figure 1d ). Reduced expression of c-Myc resulted in lower levels of ezrin and significantly diminished cell invasion on androgen treatment. Similar results were obtained with two androgen-resistant cell lines, LNCaP-R and PC3 (Supplementary Figure 2B) . We also found that the inhibitory effects of c-Myc siRNA on invasion could be reversed by simultaneously overexpressing ezrin (Figure 1d ). Taken together, these findings identify c-Myc as an important regulator of ezrin expression and PCa cell invasion.
c-Myc mediates androgen-induced ezrin gene transcription Androgens regulation of ezrin expression is a phylogenetically conserved process, observed in both rats and humans (Pang et al., 2002; Chuan et al., 2006) . Therefore, we used a bioinformatics system developed in-house, Prometheous (Vidal et al., 2007) , to search for evolutionary conserved transcription factor binding sites in the promoter of the ezrin gene. This search identified a conserved c-Myc response element, E-box (CACGTG), located 800 bases from the transcription initiation site (Figure 2a) . However, no AR response element was found in the conserved promoter regions of the ezrin gene. To characterize the function of this E-box, we cloned a 500 bp fragment of the ezrin promoter that contained the c-Myc response element into a luciferase reporter vector (Ezrin_EBox-LUC; Figure 2b , upper panel). Treatment with R1881 stimulated luciferase activity in LNCaP-FGC cells harboring the Ezrin_EBox-LUC reporter vector. However, removal of the c-Myc binding site through mutagenesis (Ezrin_EBox(mut)-LUC) blocked the stimulatory effects of androgen (Figure 2b, lower panel) . Overexpression of c-Myc enhanced ezrin promoter activity, even in the absence of androgen stimulation (Figure 2c) . Accordingly, the effect of androgen on the ezrin promoter activity was reversed by an siRNA targeting human c-Myc (Figure 2d ) and by overexpression of the c-Myc antagonist Mad (data not shown). To examine if c-Myc binds directly to the ezrin promoter, we performed chromatin immunoprecipitation (ChIP) assays. Quantitative RT-PCR (qRT-PCR) analysis showed that c-Myc binds to the ezrin promoter after R1881 treatment but not in cells treated with the vehicle control ( Figure 2e ). Control experiments using primers to amplify regions situated 1 kb downstream of the E-box showed that these regions were not present in the immunoprecipitated chromatin. Taken together, these experiments show that androgens induces ezrin gene transcription in LNCaP-FGC cells through a mechanism that involves direct binding of c-Myc to the ezrin gene promoter.
Ezrin mediates the activity of c-Myc in PCa cells
The previous results show ezrin to be a key mediator of c-Myc action on cell invasion. Conversely, we showed that cell invasion was strictly dependent on androgen and c-Myc expression alone cannot substitute the effects of androgen despite induction of ezrin expression. This suggests that additional androgen actions on ezrin protein, possibly phosphorylation are required for c-Myc-induced invasion. To examine this possibility, we analyzed androgen-induced phosphorylation in cells where c-Myc was co-transfected with VSV-G-tagged wild-type (WT) ezrin. In line with our previous results (Chuan et al., 2006) , androgen induced the phosphorylation of ezrin at Threonine 567 (T567) whereas little androgen-independent phosphorylation was observed in c-Myc overexpressing cells (Figure 3a) .
To further analyze the role of ezrin on c-Myc-induced invasion, we used two VSV-G-tagged dominant-negative ezrin variants, which bear single point mutations that lead to a change in the ezrin amino-acid sequence from threonine to alanine at position 567 and from tyrosine to Fenilalanine at position 353 (T567A and Y353F, respectively) (Gautreau et al., 1999 (Gautreau et al., , 2000 Fievet et al., 2004; Chuan et al., 2006) 
WT Ezrin 
Figure 2 Increased expression of c-Myc induces the proliferation and increases the tumorigenicity of LNCaP-FGC cells (Bernard et al., 2003) . Therefore, we measured the proliferation and tumorigenic potential of cells overexpressing c-Myc as well as different ezrin variants in the presence of androgen. The proliferation rate of cells co-expressing c-Myc and WT ezrin did not differ from that of cells expressing c-Myc alone. In contrast, coexpression of ezrin mutants diminished the effect of c-Myc on androgen-induced proliferation (Figure 3d ; Figure 3) . Similarly, anchorage-independent growth of LNCaP-FGC cells was reduced in cells co-transfected with c-Myc and ezrin mutants, as compared to cells overexpressing c-Myc alone or in combination with WT ezrin (Figure 3e ).
Ezrin regulates c-Myc levels in PCa cells
Intracellular c-Myc levels are tightly controlled by a complex mechanism that includes regulation at multiple levels, from RNA synthesis to protein degradation (Liu and Levens, 2006) . First, we investigated how ezrin influences c-Myc synthesis. The expression of WT ezrin did not influence the androgen stimulation of c-Myc mRNA levels. In contrast, both Y353F and T567A dominant-negative ezrin variants blocked androgen effects, indicating that ezrin can influence c-Myc transcription (Figure 4a) . To study the effect of ezrin on c-Myc translation and stability, we performed 35 S-methionine pulse chase and cycloheximide (CHX) chase experiments. We found that the levels of c-Myc are significantly reduced on androgen ablation whereas the half-life of the c-Myc protein is significantly extended (to 24 min) in the presence of androgen (Figure 4b ; Supplementary Figure 4A) . We next analyzed how the expression of Y353F and T567A ezrin mutants Figure 4B) . However, a dramatic reduction in the amount of c-Myc protein after 15 min of chasing time is observed in cells overexpressing the Y353F ezrin variant, indicating an increase in c-Myc degradation. Conversely, the expression of the T567A ezrin variant resulted in a significant reduction of the amount of c-Myc synthesized during androgen stimulation or the 35 S-methionine pulse period.
Ezrin phosphorylation has been linked to the activation of the PI-3K/Akt pathway (Gautreau et al., 1999) . Phosphatidylinositol 3-kinase (PI-3K) and Akt are both proto-oncogenes that are important in PCa development (Graff et al., 2000) , and their activity is regulated by androgen stimulation (Sun et al., 2003) . Akt is known to influence c-Myc levels by increasing c-Myc synthesis and decreasing c-Myc proteasomal degradation through inhibition of GSK-3b activity (Asano et al., 2004; Shi et al., 2005) . Therefore, we next investigated the hypothesis that changes in Akt activity contribute to the regulation of endogenous c-Myc expression levels by ezrin.
We analyzed the effects of different ezrin variants on endogenous c-Myc levels, as well as on Akt, GSK-3b and S6 kinase activities, in LNCaP-FGC cells (Figure 5a ). Androgen treatment increased the levels of c-Myc in cells transfected with a control vector, whereas forced overexpression of ezrin resulted in increased levels of c-Myc expression in both the presence and absence of androgen. In contrast, a significant reduction in c-Myc protein expression was detected in LNCaP-FGC cells that overexpressed ezrin mutants. Besides that, we observed a positive correlation between levels of c-Myc and Akt activities. Androgen treatment induced Akt phosphorylation in transfected control cells. Conversely, cells overexpressing WT ezrin have slightly increased basal levels of Akt phosphorylation as compared with controls and this level did not increase further with androgen treatment. No evidence of androgen-induced Akt activation was observed in cells overexpressing the T567A or the Y353F ezrin variants. Moreover, GSK-3b activity was reduced with androgen treatment in both control cells and cells overexpressing WT ezrin, whereas increased activity was observed in cells expressing ezrin dominant-negative mutants, independent of androgen status.
S6 kinase phosphorylation was also induced by androgen treatment in cells transfected with a control or a WT-ezrin expression vector. LNCaP-FGC cells transfected with the Y353F ezrin variant showed similar levels of S6 kinase phosphorylation as WT-ezrin expressing cells in androgens depleted media. However, in the presence of androgens, S6 kinase phosphorylation was significantly reduced. Cells expressing the T567A ezrin variant showed a significant reduction in S6 kinase phosphorylation, in both the presence and absence of androgen. Levels of S6 kinase activity correlate well with the rate of c-Myc synthesis, as shown in Figure 5a .
Next, we analyzed the effects of pharmacological inhibitors of proteasome, Akt and GSK-3b on c-Myc degradation in CHX chase experiments (Figure 5b) . In control and WT or Y353F ezrin variants expressing cells Akt inhibition caused a reduction on the synthesis of c-Myc protein, whereas both proteasome and GSK3b inhibitors reduced the degradation of c-Myc. In line with these results, we observed a marked inhibition of both c-Myc and ezrin protein levels (Figure 5c ) in cells treated with Akt and PI-3K pharmacological inhibitors, whereas a GSK-3b inhibitor increased the c-Myc and ezrin protein levels. PI-3K and Akt inhibition also blocked the transcriptional induction of c-Myc by androgen, whereas the GSK-3b inhibition had no effect on c-Myc mRNA levels (Supplementary Figure 4C) . Taken together, these results indicate that Akt acts downstream of ezrin and contribute to the control of cMyc protein levels on androgen stimulation.
To further test this hypothesis, we analyzed the effect of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) expression on c-Myc levels in LNCaP-FGC cells. PTEN is a tumor suppressor that antagonizes the oncogenic PI-3K/Akt pathway and is one of the most common genetic deletions observed in advanced PCa (Joshua et al., 2007; Lapointe et al., 2007) . Taking advantage of the fact that LNCaP-FGC is a PTEN-deficient PCa cell line (Vlietstra et al., 1998) , we overexpressed WT PTEN and an inactive variant (C124S mutant) and measured the effects of androgen on ezrin and c-Myc protein levels, as well as GSK-3b and Akt activities. To avoid the possible confounding effects of PI-3K inhibition on the transcriptional regulation of c-Myc by androgen, we performed the experiment in cells overexpressing c-Myc (Figure 6a ).
Androgen stimulation of control cells increased the levels of phospho-Akt as well as the levels of c-Myc and ezrin, and reduced the levels of activated GSK-3b. Forced overexpression of c-Myc resulted in increased levels of c-Myc protein and ezrin, independent of the hormonal status. In the absence of androgen, levels of phospho-Akt in cells overexpressing c-Myc increased significantly, to levels similar to those found in androgen-stimulated cells. Conversely, the levels of active GSK-3b were not influenced by the overexpression of c-Myc but were significantly reduced by androgen treatment. Overexpression of PTEN led to increased activity of GSK-3b and reduced levels of phospho-Akt, ezrin and c-Myc protein in both hormone-depleted and androgen-stimulated cells. Cells overexpressing the PTEN C124S mutant did not differ from control cells regarding Akt and GSK-3b phosphorylation. Similar to cells overexpressing c-Myc, it showed a slightly elevated level of c-Myc and ezrin in the absence of androgen. To determine the functional relationship of PTEN expression to c-Myc-initiated processes, we tested the cell invasion activity and anchorage-independent growth of cells expressing c-Myc in the presence or absence of PTEN. As shown in Figures 6b and c , restoring WT PTEN expression in LNCaP-FGC cells inhibited androgen-and c-Myc-induced invasion and anchorage-independent growth on soft agar.
Discussion
In this study, we describe a novel mechanism regulating PCa cell tumorigenesis that involves the interplay between the oncoproteins c-Myc and ezrin (Jenkins et al., 1997; Valdman et al., 2005) . These effects entail c-Myc binding to the ezrin gene promoter and induce its transcription; a process that is required for c-Mycinduced cell invasion. Conversely, inactivation of ezrin results in a reduction of c-Myc protein levels and the inhibition of c-Myc-induced invasion, proliferation and anchorage-independent growth. Ezrin controls c-Myc levels by regulating c-Myc gene expression, translation and stability, and this effect is in part mediated by effects of ezrin on Akt and GSK-3b activities. Taken together, these findings identify a positive regulatory loop, involving ezrin and c-Myc, that influences the tumorigenic properties of PCa cells. A summary of our working model can be seen in Figure 7 .
Our study reveals that c-Myc is a direct transcriptional regulator of ezrin expression in PCa cells, binding to a canonical E-box in the proximal promoter region of the ezrin gene. The induction of ezrin expression is essential for c-Myc-stimulated invasion of LNCaP-FGC cells, as shown by the fact that ezrin overexpression alone can rescue the inhibitory actions of siRNAmediated c-Myc depletion on invasion. The effects of c-Myc on invasion were blocked by the expression of dominant-negative ezrin variants. Therefore, it is likely that pathways downstream from ezrin, such as RhoA/ Cdc42 or Akt activation (D'Angelo et al., 2007; Prag et al., 2007) , are required for c-Myc-induced invasion. On the other hand, our data also support a more general role for ezrin as a positive regulator of c-Myc protein levels. Accordingly, other c-Myc activities, such as induction of cell proliferation, are also blocked by dominant-negative ezrin variants, although overexpression of ezrin alone does not significantly enhance androgen-induced cell proliferation. This indicates that c-Myc also have ezrin-independent tumor-promoting actions (Bernard et al., 2003) , some of which could contribute to the invasion-promoting activity of c-Myc.
Ezrin regulation of c-Myc expression is exerted through a complex mechanism that includes transcriptional,
Total GSK-3β translational and posttranslational effects. Expression of ezrin dominant-negative variants reduces c-Myc gene expression and the rate of c-Myc protein synthesis while enhancing protein degradation. These changes occur in parallel with a reduction in androgen-induced Akt and S6 kinase phosphorylation and increased GSK-3b activity, a well-known regulator of c-Myc turnover (Sears et al., 2000) . We observed that c-Myc expression is dramatically affected by the expression of ezrin mutants. Changes in c-Myc levels correlated with alterations in Akt and GSK-3b activation suggesting that these and possibly other signaling molecules downstream ezrin contribute to the regulation of c-Myc levels by androgens. This is further supported by our data showing that transient overexpression of the PI-3K/Akt antagonist, PTEN, causes the downregulation of c-Myc expression in PCa cells and a subsequent reduction of cell invasion, proliferation and tumorigenesis. Accordingly, pharmacological Akt inhibition also blocks the stimulatory effects of androgens on c-Myc protein and mRNA levels (Amir et al., 2003; Liao et al., 2004) whereas GSK-3b inhibition enhances c-Myc levels in the presence of androgens.
Expression of the T567A ezrin variant mainly inhibits c-Myc protein synthesis. The latter effect is likely to be exerted through inhibition of the mTOR/S6 kinase pathway, which controls translation efficiency. Remarkably, a similar inhibition of the S6 kinase pathway by the T567A ezrin variant in osteosarcoma cell lines has been recently reported (Wan et al., 2005) . The result that the overexpression of Y353F ezrin, although inhibiting c-Myc expression, did not change the amount of c-Myc S-methionine pulse lasting for 2 h is interesting. It indicates that there exists a sufficient pool of c-Myc mRNA and enough Akt/S6 kinase activity to support normal c-Myc translation, at least in the short term. Therefore, a key control mechanism exists at the level of regulation of c-Myc protein degradation, which is also influenced by ezrin and androgens.
Another important observation is that the c-Myc/ ezrin regulatory loop controlling cell invasion is active in both androgen-dependent and -independent PCa cells. This suggests that androgen refractory tumor cells may use other factors to control ezrin and c-Myc expression when androgens levels are reduced (Feldman and Feldman, 2001) . Several of the androgen-regulated signaling pathways have been shown to be constitutively active in hormone therapy refractory prostate tumors, including the PI-3K/Akt and Src-activated pathways. The latter pathway have a key role in ezrin activation (Murillo et al., 2001; Sawyer, 2004; Wu et al., 2004) . Additional studies are needed to identify the ARindependent mechanism responsible for c-Myc and ezrin expression and activation in hormone refractory PCa.
In summary, our study reveals a novel regulatory loop controlling PCa cell invasion that involves ezrin and c-Myc. The proposed mechanism is likely to be relevant to PCa progression, where increased ezrin and c-Myc protein expression is often observed.
Materials and methods
Materials
Synthetic androgen R1881 was obtained from Amersham (Braunschweig, Germany). The AR antagonist bicalutamide (Casodex) was generously donated by AstraZeneca (Stockholm, Sweden). LY294002 was obtained from Cell Signaling Technology (Beverly, MA, USA), SH-6 and GSK inhibitor XV were obtained from Calbiochem (Neu Isenburg, Germany). Bortezomib was obtained from LC Laboratories (Woburn, MA, USA). Sea plaque agarose was purchased from Cambrex (Rockland, ME, USA)
Cell culture, hormone and drug treatments The PCa cell lines LNCaP-FGC, LNCaP-R and PC3 were cultured as previously described (Bonaccorsi et al., 2000; Pang et al., 2004b) . Bicalutamide (10 mM), LY294002 (10 mM), GSK inhibitor XV (0.6 nM) and SH-6 (10 mM) were added to the media 2 h before hormone stimulation. The protein synthesis inhibitor CHX (10 mg/ml) was added 30 min before hormone stimulation.
Plasmids and cell transfection
The plasmids bearing the different VSV-G-tagged variants of human ezrin has been described previously (Chuan et al., 2006) . The c-Myc expression plasmid was a generous gift from Maria Henriksson. siRNA targeting human ezrin, c-Myc and luciferase (control) was obtained from Qiagen (Hilden, Germany). Transfections were performed using the Amaxa Nucleofector (Amaxa, Gaithersburg, MD, USA) according to the manufacturer's instructions. Cells were treated 24 h after transfection.
RNA extraction, cDNA synthesis and real-time-PCR These procedures were carried out as earlier described (Chuan et al., 2006) . All measurements were performed in triplicate for each sample and normalized to the internal control gene, b-actin. Four independent experiments were performed. The primers used were: for b-actin, 5 0 -CTGGCTGCTGACCG AGG-3 0 and 5 0 -GAAGGTCTCAAACATGATCTGGGT-3 0 ; for c-Myc, 5 0 -CGCCCAAGTCCTGCGCCTCGCA-3 0 and 5 0 -CCTCCTCTGGCGCTCCAAGACGT-3 0 . The annealing temperature was 58 1C.
Western blotting
The western blotting procedure was carried out as described earlier (Chuan et al., 2006) . Mouse anti-human ezrin antibody was obtained from Neomarker (Fremont, CA, USA). Mouse anti-c-Myc antibody (9E10 clone) was obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Mouse antiphospho-Thr567 Ezrin antibody was obtained from BD Biosciences (San Jose, CA, USA). Mouse anti-phospho-GSK-3b (Tyr216) antibody was from Transduction Laboratories (Lexington, KY, USA). Rabbit anti-phospho-Akt (Ser473), rabbit anti-phospho-S6 kinase (Thr389), rabbit anti-Akt, rabbit anti-GSK-3b and mouse anti-human PTEN antibodies were purchased from Cell Signaling Technology. Mouse anti-human b-actin antibody was obtained from Sigma (St Louis, MO, USA).
Matrigel invasive assay
This procedure was carried out as previously described (Chuan et al., 2006) . Four independent experiments were performed. In each experiment, Matrigel invasion for each experimental group was measured in triplicate.
Luciferase reporter assay A region of the ezrin gene promoter harboring a conserved E-box, a putative binding site for c-Myc, was PCR-amplified using the primers: 5 0 -CTAGCTAGCTAGGCCACTTAACCA GAGC-TTCG-3 0 and 5 0 -CTAGCAAGCTAGGCAGTGC TCCGTGTGCTC-3 0 and ligated into the NheI site of the pGL2 luciferase reporter plasmid (Promega, Madison, WI, USA) and named Ezrin-EBox-LUC. Mutagenesis within the E-box region of the Ezrin-EBox-LUC plasmid was performed using the QuickChange Mutagenesis kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions and referred to as Ezrin-EBox(mut)-LUC. All the resulted constructs were verified by sequencing. The LNCaP-FGC cells were transfected with the luciferase reporter constructs together with a plasmid containing b-galactosidase using the Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) reagent according to the manufacturer's instructions. Transfected cells were cultured in phenol red-free RPMI 1640 containing 5% dextran-coated charcoal-treated fetal bovine serum (DCC-FBS) for 24 h before stimulation with 10 nM R1881 or a vehicle control for a further 1 h before lysis with 200 ml Reporter Lysis Buffer (Promega). Lysates were then assayed for luciferase activity using Promega Luciferase Assay Substrate. Galactosidase activity was measured using spectrophotometric assay as described (Greenhalgh et al., 2002) . Luciferase activity was normalized to b-galactosidase activity.
Soft agar colony formation assay
This assay was carried out as previously described (Bernard et al., 2003) . Each plate was seeded with 1 Â 10 5 cells. Every 3 days, 1 ml of fresh media was added to the cells. After 14 days, the top layer of the culture was stained with 0.2% iodonitrotetrazolium chloride, and colonies larger than 0.1 mm in diameter were counted.
Chromatin immunoprecipitation
LNCaP-FGC cells were cultivated and treated as described above. Chromatin extracts were prepared as previously described (O'Sullivan et al., 2002) . Mouse anti-human c-Myc antibody (or mouse IgG as control) was used to immunoprecipitate c-Myc-bound chromatin fragments. To quantify the amount of DNA bound to c-Myc or controls, we performed real-time PCR (RT-PCR) as described above. The oligonucleotides 5 0 -CAGGGGGAAGTCAGGAAAAC-3 0 and 5 0 -TGCCAGTCACGTCAAAAGAG-3 0 were used to amplify the putative c-Myc binding site in the human ezrin promoter. The oligonucleotides 5 0 -ACTTGAAACCAACCGTGAGG-3 0 and 5 0 -CCTGCCATCGTTTCATTTTT-3 0 were used to amplify a region 1000 bp downstream the putative E-box and were used as controls. The annealing temperature used in both PCR reactions was 58 1C.
Pulse-chase assay LNCaP-FGC cells were starved in RPMI 1640 lacking L-methionine for 1 h. Cells were labeled with 500 mCi/ml 35 S-methionine (GE Healthcare, Chalfont St Giles, Buckinghamshire, UK) for 2 h at 37 1C. After labeling, cells were washed once and incubated with RPMI 1640 supplemented with 15 mM Lmethionine and 5% DCC-FBS, in the presence of 10 nM R1881 (or vehicle control) for the indicated chase times. Cells were harvested and c-Myc was immunoprecipitated from equal amount of cells using 1 mg of the c-Myc monoclonal antibody (Clone N262; Santa Cruz Biotechnology). The immunoprecipitated material was subjected to SDS-polyacrylamide gel electrophoresis and labeled c-Myc was visualized by autoradiography.
Cycloheximide chase experiment LNCaP-FGC cells were kept in phenol red-free RPMI 1640 containing 5% DCC-FBS before stimulation with 10 nM R1881 for 2 h. After stimulation, cells were washed once with phosphate-buffered saline and incubated with medium containing 10 mg/ml CHX in the presence of 10 nM R1881 or vehicle, 0.1% ethanol for the indicated times. Cells were harvested and western blotting was performed to check c-Myc protein levels.
MTT proliferation assay
LNCaP-FGC cells were cultured in 96-well plates (5000 cells per well) in phenol red-free RPMI 1640 containing 5% DCC-FBS and cultured for 24 h. Cells were then stimulated with 10 nM R1881 or a vehicle control. Proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay kit (Roche Diagnostics, Indianapolis, IN, USA), following the manufacturer's instructions.
